Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 26.00

From 52W high−17.38%

Volume8.29M

Market capCNY 13.06B

P/E (TTM)−13.5x

P/S (TTM)16.0x

Div yield—

Key dataSep 18, 2026

Open

CNY 26.00

From 52W high

−17.38%

Volume

8.29M

Market cap

CNY 13.06B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−16.9x

P/E (TTM)

−13.5x

RSI (14)

44.6

MomentumView details →

1D Return

−6.22%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−13.5x

EV/EBITDA

−16.9x

EV/Sales

17.4x

P/S (TTM)

16.0x

P/B (TTM)

122.3x

ProfitabilityView details →

Gross Margin

88.61%

Net Margin

−123.38%

EBITDA Margin

−103.01%

ROE (TTM)

−860.88%

ROA (TTM)

−20.13%

Asset Turnover

0.16x

GrowthView details →

Revenue YoY

+321.05%

EPS YoY

+18.34%

FCF YoY

+57.17%

Revenue CAGR 3Y

+188.02%

EPS CAGR 3Y

+6.90%

EBITDA YoY

—

MomentumView details →

1D Return

−6.22%

YTD Return

—

1Y Return

—

RSI (14)

44.6

vs 50D SMA

−10.85%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

22.56x

Current Ratio

0.88x

Quick Ratio

0.79x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−CNY 0.65

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

0.00%

Financials snapshotView financials →

Revenue (TTM)

745.32M

Net Income (TTM)

−919.55M

Op. CF (TTM)

−307.77M

Latest newsMore news →

Mabwell Bioscience reported its H1 2026 semi-annual results on August 30, with revenue of 313 million yuan (up 209.04% year-on-year) and a net loss attributable to shareholders of 522 million yuan, narrowing from a loss of 551 million yuan in the same period last year.21d ago

Mabwell (Shanghai) Bioscience Co., Ltd. received approval from the National Medical Products Administration for a clinical trial application of its 9MW5211 injection for vitiligo.66d ago

Similar companies

BridgeBio Pharma, Inc.BBIO Duality Biotherapeutics, Inc.09606.HK Halozyme Therapeutics, Inc.HALO Jiangsu Zenergy Battery Technologies Group Co., Ltd.03677.HK 生物股份600201.SH BioMarin Pharmaceutical Inc.BMRN Find similar companies →

Latest newsMore news →

Mabwell Bioscience reported its H1 2026 semi-annual results on August 30, with revenue of 313 million yuan (up 209.04% year-on-year) and a net loss attributable to shareholders of 522 million yuan, narrowing from a loss of 551 million yuan in the same period last year.21d ago Mabwell (Shanghai) Bioscience Co., Ltd. received approval from the National Medical Products Administration for a clinical trial application of its 9MW5211 injection for vitiligo.66d ago